Improvement in quality of oocytes in polycystic ovarian syndrome in programs of in vitro fertilization

被引：17

作者：

Vartanyan, E. V. ^{[1
,2
]}

Tsaturova, K. A. ^{[1
]}

Devyatova, E. A. ^{[1
]}

Mikhaylyukova, A. S. ^{[1
]}

Levin, V. A. ^{[1
]}

Petuhova, N. L. ^{[1
]}

Markin, A. V. ^{[1
]}

Steptsova, E. M. ^{[1
]}

机构：

[1] Clin Assisted Reprod Technol Test Tube Babies LLC, Shchukinskaya St 2, Moscow 123182, Russia

[2] Peoples Friendship Univ Russia, Dept Obstet Gynecol & Reprod Med, Moscow, Russia

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 2017年 / 33卷

关键词：

PCOS; infertility; inositol; myo-inositol; IVF; pregnancy; INSULIN-SECRETION; MYOINOSITOL; CONSENSUS; WOMEN; PCOS;

D O I：

10.1080/09513590.2017.1399699

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inositol therapy is aimed at improving the quality of oocytes during preconception care in patients with polycystic ovarian syndrome (PCOS), a cause of infertility and reproductive dysfunction. The objectives of this observational comparative multicentre study were to evaluate the effectiveness of inositol in improving the quality of oocytes/embryos and IVF cycle outcome. Group 1 patients (N = 133) received inositol 1000mg (Inofert or Nutrilinea) +folic acid 0.1mg. Group 2 consisted of patients with preserved ovarian reserve without PCOS (N = 137), not administered inositol prior to pregnancy. Effectiveness criteria were numbers of mature oocytes and good quality embryos, pregnancy rates per ET, 'take home baby' index and miscarriage rates. Pregnancy rates per ET (87.0% vs. 87.4%), 'take home baby' index (79.6% vs. 89.4%) and miscarriage rates (14.3% vs. 10.6%) were comparable. Use of inositol in patients with PCOS during preconception care is an effective method allowing improvement of oocytes quality and positively affecting IVF cycle prognosis. High pregnancy rates per ET and ` take home baby' index after treatment are justifying inositol usage in patients with PCOS and infertility.

引用

页码：8 / 11

页数：4

共 15 条

[1] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J].

Chang, J ;

Azziz, R ;

Legro, R ;

Dewailly, D ;

Franks, S ;

Tarlatzis, BC ;

Fauser, B ;

Balen, A ;

Bouchard, P ;

Dahlgren, E ;

Devoto, L ;

Diamanti, E ;

Dunaif, A ;

Filicori, M ;

Homburg, R ;

Ibanez, L ;

Laven, J ;

Magoffin, D ;

Nestler, J ;

Norman, RJ ;

Pasquali, R ;

Pugeat, M ;

Strauss, J ;

Tan, S ;

Taylor, A ;

Wild, R ;

Wild, S ;

Ehrmann, D ;

Lobo, R .

FERTILITY AND STERILITY, 2004, 81 (01) :19-25

[2] Results from the International Consensus Conference on Myo-inositol and D-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS [J].

Facchinetti, Fabio ;

Bizzarri, Mariano ;

Benvenga, Salvatore ;

D'Anna, Rosario ;

Lanzone, Antonio ;

Soulage, Christophe ;

Di Renzo, Gian Carlo ;

Hod, Moshe ;

Cavalli, Pietro ;

Chiu, Tony T. ;

Kamenov, Zdravko A. ;

Bevilacqua, Arturo ;

Carlomagno, Gianfranco ;

Gerli, Sandro ;

Oliva, Mario Montanino ;

Devroey, Paul .

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 195 :72-76

[3]

Fonseca V, 2011, METABOLIC SYNDROME, P272

[4] The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome [J].

Fulghesu, AM ;

Villa, P ;

Pavone, V ;

Guido, M ;

Apa, R ;

Caruso, A ;

Lanzone, A ;

Rossodivita, A ;

Mancuso, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :644-648

[5] Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients [J].

Genazzani, Alessandro D. ;

Prati, Alessia ;

Santagni, Susanna ;

Ricchieri, Federica ;

Chierchia, Elisa ;

Rattighieri, Erica ;

Campedelli, Annalisa ;

Simoncini, Tommaso ;

Artini, Paolo G. .

GYNECOLOGICAL ENDOCRINOLOGY, 2012, 28 (12) :969-973

[6]

Gromova OA, 2013, OBSTET GYNECOL, V51, P12

[7]

Heffner L, 2014, REPROD SYSTEM GLANCE, P112

[8]

Kamalanathan Sadishkumar, 2013, Indian J Endocrinol Metab, V17, P37, DOI 10.4103/2230-8210.107830

[9] Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome [J].

Morin-Papunen, LC ;

Vauhkonen, I ;

Koivunen, RM ;

Ruokonen, A ;

Tapanainen, JS .

HUMAN REPRODUCTION, 2000, 15 (06) :1266-1274

[10]

Nazarenko T. A., 2008, POLYCYSTIC OVARIAN S, P208

← 1 2 →